IL6 and prostate cancer: It is of note that STAT3 inhibition abrogate IL-6-dependent conversion of ALDH (low) prostate cancer cells to ALDH(high) [55] whereas STAT3 activation induces a melanoma-initiating cell phenotype that could favor chemotherapy resistance and relapse [68].